UNSPSC 51143408: Naproxen/sumatriptan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS.

UNSPSC 51143408 Naproxen/sumatriptan is a Commodity code that in practice encompasses a broader range of pharmaceutical procurement by state and local governments than the code name alone suggests. Recent solicitations show state and local buyers acquiring naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs through competitive bidding and cooperative purchasing vehicles. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving participating state and local government facilities across multiple states including Oregon). The work ranges from annual supply agreements with quarterly deliveries to manufacturers through authorized wholesalers, to exploratory requests for information on direct contracting models outside traditional pharmacy benefit manager arrangements.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida posted IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2026, response deadline and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs for self-insured health plans and state agencies, signaling exploratory procurement that will likely inform a formal RFP. The Minnesota Department of Administration's MMCAP released RFP S1070000015802 on January 20, 2026, with a March 26, 2026, response deadline to establish multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with awards effective July 1, 2026, and a two-year contract term. Vendors pursuing MMCAP must certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two authorized wholesalers, provide comprehensive insurance including $5 million commercial general liability per occurrence, and accept a 3 percent administrative fee on all purchases.